These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 9399697)

  • 1. Cerebral changes and cerebrospinal fluid beta-amyloid in Alzheimer's disease: a study with quantitative magnetic resonance imaging.
    Schröder J; Pantel J; Ida N; Essig M; Hartmann T; Knopp MV; Schad LR; Sandbrink R; Sauer H; Masters CL; Beyreuther K
    Mol Psychiatry; 1997; 2(6):505-7. PubMed ID: 9399697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain metabolic correlates of CSF Tau protein in a large cohort of Alzheimer's disease patients: A CSF and FDG PET study.
    Chiaravalloti A; Barbagallo G; Ricci M; Martorana A; Ursini F; Sannino P; Karalis G; Schillaci O
    Brain Res; 2018 Jan; 1678():116-122. PubMed ID: 29066367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Critical Comparison of Different Biomarkers for Alzheimer's Disease in a Clinical Setting.
    Weise D; Tiepolt S; Awissus C; Hoffmann KT; Lobsien D; Kaiser T; Barthel H; Sabri O; Gertz HJ
    J Alzheimers Dis; 2015; 48(2):425-32. PubMed ID: 26402006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid cellular uptake of Alzheimer amyloid betaA4 peptide by cultured human neuroblastoma cells.
    Ida N; Masters CL; Beyreuther K
    FEBS Lett; 1996 Sep; 394(2):174-8. PubMed ID: 8843158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reverse relationship between beta-amyloid precursor protein and beta-amyloid peptide plaques in Down's syndrome versus sporadic/familial Alzheimer's disease.
    Egensperger R; Weggen S; Ida N; Multhaup G; Schnabel R; Beyreuther K; Bayer TA
    Acta Neuropathol; 1999 Feb; 97(2):113-8. PubMed ID: 9928821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
    Susanto TA; Pua EP; Zhou J;
    J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the diagnostic sensitivity of MRI, CBF-SPECT, FDG-PET and cerebrospinal fluid biomarkers for detecting Alzheimer's disease in a memory clinic.
    Morinaga A; Ono K; Ikeda T; Ikeda Y; Shima K; Noguchi-Shinohara M; Samuraki M; Yanase D; Yoshita M; Iwasa K; Mastunari I; Yamada M
    Dement Geriatr Cogn Disord; 2010; 30(4):285-92. PubMed ID: 20861634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease.
    Ossenkoppele R; Mattsson N; Teunissen CE; Barkhof F; Pijnenburg Y; Scheltens P; van der Flier WM; Rabinovici GD
    Neurobiol Aging; 2015 Aug; 36(8):2340-7. PubMed ID: 25990306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissociation of amyloid biomarkers in PET and CSF in Alzheimer's disease: a case report.
    Schroeter ML; Tiepolt S; Marschhauser A; Thöne-Otto A; Hoffmann KT; Barthel H; Obrig H; Sabri O
    BMC Neurol; 2015 Aug; 15():152. PubMed ID: 26303364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers in Swedish familial Alzheimer's disease.
    Thordardottir S; Ståhlbom AK; Ferreira D; Almkvist O; Westman E; Zetterberg H; Eriksdotter M; Blennow K; Graff C
    J Alzheimers Dis; 2015; 43(4):1393-402. PubMed ID: 25182737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accurate prediction of histologically confirmed Alzheimer's disease and the differential diagnosis of dementia: the use of NINCDS-ADRDA and DSM-III-R criteria, SPECT, X-ray CT, and APO E4 medial temporal lobe dementias. The Oxford Project to Investigate Memory and Aging.
    Jobst KA; Barnetson LP; Shepstone BJ
    Int Psychogeriatr; 1997; 9 Suppl 1():191-222; discussion 247-52. PubMed ID: 9447442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal Fluid Biomarkers are Differentially Related to Structural and Functional Changes in Dementia of the Alzheimer's Type.
    Malpas CB; Saling MM; Velakoulis D; Desmond P; Hicks RJ; Zetterberg H; Blennow K; O'Brien TJ
    J Alzheimers Dis; 2018; 62(1):417-427. PubMed ID: 29439322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers.
    Kester MI; Goos JD; Teunissen CE; Benedictus MR; Bouwman FH; Wattjes MP; Barkhof F; Scheltens P; van der Flier WM
    JAMA Neurol; 2014 Jul; 71(7):855-62. PubMed ID: 24818585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Applied multimodal diagnostics in a case of presenile dementia.
    Schönecker S; Brendel M; Huber M; Vollmar C; Huppertz HJ; Teipel S; Okamura N; Levin J; Rominger A; Danek A
    BMC Neurol; 2016 Aug; 16():131. PubMed ID: 27506761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The differentiation of depression from dementia by temporal lobe magnetic resonance imaging.
    O'Brien JT; Desmond P; Ames D; Schweitzer I; Tuckwell V; Tress B
    Psychol Med; 1994 Aug; 24(3):633-40. PubMed ID: 7991745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between naturally occurring anti-amyloid β autoantibodies and medial temporal lobe atrophy in Alzheimer's disease.
    Kimura A; Takemura M; Saito K; Yoshikura N; Hayashi Y; Inuzuka T
    J Neurol Neurosurg Psychiatry; 2017 Feb; 88(2):126-131. PubMed ID: 27330118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
    Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
    Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease.
    Brier MR; Gordon B; Friedrichsen K; McCarthy J; Stern A; Christensen J; Owen C; Aldea P; Su Y; Hassenstab J; Cairns NJ; Holtzman DM; Fagan AM; Morris JC; Benzinger TL; Ances BM
    Sci Transl Med; 2016 May; 8(338):338ra66. PubMed ID: 27169802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Visual Ratings of Medial Temporal Lobe Atrophy Correlate with CSF Tau Indices in Clinical Variants of Early-Onset Alzheimer Disease.
    Granadillo E; Paholpak P; Mendez MF; Teng E
    Dement Geriatr Cogn Disord; 2017; 44(1-2):45-54. PubMed ID: 28675901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal Fluid C-C Motif Chemokine Ligand 2 Correlates with Brain Atrophy and Cognitive Impairment in Alzheimer's Disease.
    Kimura A; Yoshikura N; Hayashi Y; Inuzuka T
    J Alzheimers Dis; 2018; 61(2):581-588. PubMed ID: 29171996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.